A phase 1 clinical trial of venetoclax and rituximab combination therapy was shown to be an effective chemo-free treatment option for patients with difficult-to-treat chronic lymphocytic leukemia.
Menu
Browsing: Cancer
A newly identified biomarker may predict treatment response in patients with chronic myelogenous leukemia, according to a Northwestern Medicine study.
In recent Northwestern Medicine clinical trials, an experimental drug improved survival rates for patients with advanced midgut neuroendocrine tumors compared to a standard therapy.
A paper published in Molecular Cell provides new insight into a protein complex called COMPASS and its function during histone methylation, a key modification that regulates gene expression.
A surgical procedure called a pelvic exenteration may be curative for more than half of women with a form of advanced cervical cancer who have failed other treatments.
Northwestern Medicine scientists have identified the unique targets of two enzymes that activate ubiquitination, a key modification of proteins that controls a variety of cellular processes.
A novel national trial for people with no established alternative to treat their rare cancers is being co-led by Northwestern Medicine investigators, who helped conceive of and develop the project.
The addition of the drug cetuximab to standard chemoradiation reduced the incidence of relapse for patients with anal cancer, but was associated with significant adverse effects, according to recent Northwestern Medicine clinical trials.
A recent clinical trial assessed the efficacy and safety of the drug ibrutinib in patients with Waldenstrom’s macroglobulineaemia, a type of non-Hodgkin lymphoma, who were not responding to other treatments.
Northwestern Medicine scientists have identified a molecular therapy to prevent the growth of a rare pediatric leukemia.